Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
about
Single dose antibiotics for treating uncomplicated urinary tract infection in non-pregnant womenSingle dose antibiotics for treating uncomplicated urinary tract infection in non-pregnant womenMolecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceSusceptibility of urinary tract bacteria to fosfomycinOral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coliIn vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteriaDecreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines.Emerging drugs for bacterial urinary tract infections.Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study.Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.Role of old antimicrobial agents in the management of urinary tract infection.Initial characterization of Fom3 from Streptomyces wedmorensis: The methyltransferase in fosfomycin biosynthesis.Elevated Expression of GlpT and UhpT via FNR Activation Contributes to Increased Fosfomycin Susceptibility in Escherichia coli under Anaerobic Conditions.Identification of a second two-component signal transduction system that controls fosfomycin tolerance and glycerol-3-phosphate uptake.Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake.Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines.Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli.Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
P2860
Q24235080-3A61718E-5655-4C3A-AA5B-EDE164AB562EQ24241173-201B077E-4886-432D-8403-45C086C20E9BQ26853135-B09A3870-CBAD-4A6C-96E6-7ABD79FF3AE3Q33494283-90E326D2-1042-4B28-92F7-E372A0BF3582Q34108735-F672AD80-8876-456C-8EB4-A82E68B1FDE8Q34301565-8BE1B9F4-ACB8-491B-BAA7-F984925BBB23Q34352165-08DBCBA9-62B0-4465-B434-199DEB674790Q35031841-A75EB162-E68F-4EFB-91EC-AE138B0E4880Q36150606-075697E6-3BE3-4397-9845-118D10EAE5ABQ37374128-0BF93475-77EE-4444-AAA7-06C9C4D5A513Q37957839-9FA1929F-E5F0-4EE9-AD91-018E60C25BFFQ38160759-29E13C8F-E00D-47E1-B651-F3B1DDFFF728Q38725968-E7118ABF-E546-48B2-A6CE-2BFA5D53816BQ38832723-71A11CD1-1DDF-4941-BE24-7F1411BFC89EQ40418915-79268A27-DE8C-43F6-9AE1-4D38B698C730Q41066081-D7646C75-AD6E-47F5-9C05-5DF57B329FC7Q41597001-9C301798-F40C-4BC1-BC97-836DA806FF39Q41908390-7377159C-102C-4ECD-A942-05C3213B3C91Q42277205-5ED714E9-9738-4A8A-BB82-B2F5692F8D42Q42582994-C93C1FC4-67B9-47BD-BBAC-F43E5258638EQ46614086-ADC3DC8A-204D-49DB-BAAD-5EFFCCEF67E1Q46705551-25AC7EC7-67C7-4628-BD2E-7E1ADD0DD22CQ46713329-E7024CD1-8E11-4C0A-A065-F13967B660F0
P2860
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@ast
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@en
type
label
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@ast
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@en
prefLabel
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@ast
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@en
P1476
Why fosfomycin trometamol as first line therapy for uncomplicated UTI?
@en
P2093
P356
10.1016/S0924-8579(03)00231-0
P478
22 Suppl 2
P577
2003-10-01T00:00:00Z